Financial Performance - For the fiscal year ending December 31, 2025, the company reported revenue of RMB 790.5 million, an increase of 3.8% from RMB 761.8 million in 2024[3]. - The company's gross profit for the same period was RMB 580.7 million, reflecting a growth of 4.5% compared to RMB 555.9 million in the previous year[2]. - Net profit decreased by 26.2% to RMB 183.8 million from RMB 248.9 million in 2024, primarily due to impairment losses and fair value changes of investments[3]. - Adjusted net profit, excluding non-Hong Kong Financial Reporting Standards items, increased by 6.0% to RMB 298.5 million from RMB 281.7 million in 2024[3]. - The gross profit margin improved to 73.5%, an increase of 0.5 percentage points year-on-year[10]. - The group achieved a revenue of RMB 790.5 million in 2025, representing a growth of 3.8% compared to the previous year[10]. - The operating profit decreased to RMB 317,496,000 in 2025 from RMB 326,821,000 in 2024, indicating a decline of 2.0%[74]. - The pre-tax profit for 2025 was RMB 230,980,000, a decrease from RMB 302,733,000 in 2024, reflecting a decline of about 23.7%[97]. - Basic and diluted earnings per share for 2025 were RMB 0.32, compared to RMB 0.44 in 2024, representing a decrease of 27.3%[74]. - The company reported a foreign exchange loss of RMB 22,071,000 in 2025, compared to a gain of RMB 17,802,000 in 2024, impacting overall comprehensive income[75]. Product Development and Innovation - The company is expanding into new areas such as neurosurgery and brain-computer interfaces, with innovative solutions targeting conditions like hematoma and brain tumors[9]. - The company has developed several pioneering products, including the world's first stent system for intracranial atherosclerosis and the first domestically approved flow-diverting stent for treating cerebrovascular diseases[8]. - The group launched 6 new products registered with NMPA, enhancing its product matrix in the neuro-intervention field[11]. - The company has a total of 12 hemorrhagic stroke treatment products in its pipeline, with 8 products already approved for commercialization, including embolization coils and flow-diverting stents[23]. - The company is actively developing new products, with anticipated approvals for the Tubridge® series of flow-diverting stents expected in 2024 and 2026[22]. - The company has received breakthrough medical device designation from the FDA for its atherosclerosis narrowing products, allowing for expedited development[22]. Market Expansion and Sales - The overseas business experienced strong growth, with revenue increasing by 39.4% year-on-year, contributing to sales growth across various regions including Asia-Pacific, North America, Latin America, and Europe[3]. - The company holds the largest domestic market share in China's neuro-interventional medical device sector, with 10 core products commercialized in 36 countries, and overseas revenue accounting for 13% of total revenue[8]. - International business revenue reached RMB 104.9 million, a year-on-year increase of 39.4%, accounting for 13% of total revenue[18]. - The sales team expanded to cover nearly 3,800 hospitals, including over 2,100 tertiary hospitals and all top 100 stroke centers in China[12]. - The group supported over 66,700 neuro-intervention surgeries in 2025, a growth of over 30% year-on-year[12]. Financial Position and Assets - Total assets as of December 31, 2025, were RMB 1,498,693,000, an increase from RMB 1,370,075,000 in 2024[76]. - Non-current assets increased significantly to RMB 609,227,000 in 2025 from RMB 672,461,000 in 2024, primarily due to investments in property and equipment[76]. - Trade and other receivables rose to RMB 362,002,000 in 2025, up from RMB 176,991,000 in 2024, indicating improved collection efforts[76]. - The company holds structured deposits totaling RMB 406,779,000 as of December 31, 2025, with an expected annual return rate of 1.35%–1.86%[103]. - The total non-current assets in China amounted to RMB 486,272,000 as of December 31, 2025, compared to RMB 321,719,000 in 2024, reflecting a substantial increase of approximately 51.2%[88]. Research and Development - Research and development expenses for 2025 totaled RMB 108,768,000, down from RMB 150,523,000 in 2024, a reduction of about 27.8%[94]. - The company has established a research team of 113 members, with over 65% holding doctoral or master's degrees, focusing on innovative solutions in neurointerventional medical devices[65]. - The company aims to enhance its innovation capabilities and develop a comprehensive solution ecosystem for brain diseases, focusing on both internal R&D and external collaborations[71]. Corporate Governance and Shareholder Matters - The company has complied with all applicable corporate governance codes during the reporting period[151]. - The company proposed a final dividend of HKD 0.09 per share, subject to shareholder approval at the 2025 Annual General Meeting[157]. - The company plans to issue new shares under a scrip dividend scheme, pending approval from shareholders and the stock exchange[157]. - The share transfer registration will be suspended from July 6, 2026, to July 8, 2026, to determine eligibility for the proposed final dividend[160]. - The company expresses gratitude to shareholders, management, employees, business partners, and customers for their support and contributions[161].
微创脑科学(02172) - 2025 - 年度业绩